Predicting the risk of recurrent venous thromboembolism the Austrian study on recurrent venous thromboembolism (AUREC)

Hamostaseologie

Volumn 33, Issue 3, 2013, Pages 201-209

  Kyrle, P A ^a   Eischer, L ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Prediction; Recurrence; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING INHIBITOR; D DIMER; ESTROGEN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN;

ANTICOAGULANT THERAPY; ARTICLE; CANCER PATIENT; CLINICAL DECISION MAKING; DEEP VEIN THROMBOSIS; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; LABORATORY TEST; LUNG EMBOLISM; OBESITY; POSTTHROMBOSIS SYNDROME; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK FACTOR; SCREENING; SEX DIFFERENCE; SURGICAL TECHNIQUE; THROMBOPHILIA; VEIN OCCLUSION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

EID: 84883062775     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-13-03-0018     Document Type: Article

References (53)

1. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005; 365: 1163-1174.
2. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010; 376: 2032-2039.
3. Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
4. Prandoni P, Noventa F, Ghirarduzzi A et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205.
5. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
6. Eichinger S, Weltermann A, Minar E et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164: 92-96.
7. Baglin T, Douketis J, Tosetto A et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010; 8: 2436-2442.
8. Iorio A, Kearon C, Filippucci E et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170: 1710-1716.
9. Christiansen SC, Cannegieter SC, Koster T et alR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293: 2352-2361.
10. Cushman M, Glynn RJ, Goldhaber SZ et al. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost 2006; 4: 2199-2203.
11. Le Gal G, Kovacs MJ, Carrier M et al. Risk of recurrent venous thromboembolism after a first oestrogen- associated episode. Data from the REVERSE cohort study. Thromb Haemost 2010; 104: 498-503.
12. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
13. Kyrle PA, Minar E, Bialonczyk C et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-2563.
14. Mc Rae S, Tran H, Schulman S et al. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006; 368: 371-378.
15. Douketis J, Tosetto A, Marcucci M et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011; 24: 342:d813.
16. Eichinger S, Hron G, Bialonczyk C et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678-1683.
17. Stain M, Schönauer V, Minar E et al. The postthrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost 2005; 3: 2671-2676.
18. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-774.
19. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC randomized study. Circulation 2005; 112: 416-422.
20. White RH, Zhou H, Kim J, Romano PS. A population- based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med 2000; 160: 2033-2041.
21. Carrier M, Rodger MA, Wells PS et al. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 2001; 9: 1119-1125.
22. Tan M, Mos IC, Klok FA, Huisman MV. Residual venous thrombosis as predictive factor for recurrent venous thromboembolism in patients with proximal deep vein thrombosis: a systematic review. Br J Haematol 2011; 153: 168-178.
23. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332-338.
24. Eichinger S, Pabinger I, Stümpflen A et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624-628.
25. Eichinger S, Minar E, Hirschl M et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A mutation in the prothrombin gene. Thromb Haemost 1999; 81: 14-17.
26. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
27. Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114.
28. Segal JB, Brotman DJ, Necochea AJ et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009; 301: 2472-2485.
29. Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-462.
30. Legnani C, Benilde C, Michela C et al. High plasma levels of factor VIII and risk of recurrence of vevnous thromboembolism. Br J Haematol 2004; 124: 504-510.
31. Eichinger S, Stümpflen A, Hirschl M et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-569.
32. Den Heijer M, Willems HP, Blom HJ et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 109: 139-144.
33. Hoke M, Kyrle PA, Minar E et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005; 94: 787-790.
34. Eichinger S, Schönauer V, Weltermann A et al. Thrombin-activable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-3776.
35. Traby L, Kollars M, Eischer L, Eichinger S, Kyrle PA. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS One 2012; 7: e51447.
36. Coppens M, Reijnders JH, Middeldorp S et al. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 2008; 6: 1474-1477.
37. Weltermann A, Eichinger S, Bialonczyk C et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 2003; 1: 28-32.
38. Hron G, Eichinger S, Weltermann A et al. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost 2006; 4: 752-756.
39. Brummel-Ziedins, KE, Vossen CY, Butenas S et al. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005; 3: 2497-2505.
40. Hron G, Kollars M, Binder BR et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402.
41. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 2008; 54: 2042-2048.
42. Tripodi A, Legnani C, Chantarangkul V et al. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008; 6: 1327-1333.
43. Besser M, Baglin C, Luddington R et al. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008; 6: 1720-1725.
44. Takach Lapner S, Kearon C. Diagnosis and management of pulmonary embolism. BMJ 2013; 346: f757.
45. Palareti G, Legnani C, Cosmi B et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003: 108: 313-318.
46. Eichinger S, Minar E, Bialonczyk C et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071-1074.
47. Rodger MA, Kahn SR, Wells PS et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179: 417-426.
48. Verhovsek M, Douketis JD, Yi Q et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149: 481-490.
49. Douketis J, Tosetto A, Marcucci M et al. Patientlevel meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010; 153: 523-531.
50. Palareti G, Cosmi B, Legnani C et al. PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789.
51. Tosetto A, Iorio A, Marcucci M et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism. A proposed prediction score (DASH), J Thromb Haemost 2012; 10: 1019-1025.
52. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121: 1630-1636.
53. Louzada ML, Carrier M, Lazo-Langner A et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126: 448-454.